市场调查报告书
商品编码
1316273
全球控释给药市场 - 2023-2030 年Global Controlled Release Drug Delivery Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2022 年,全球控释给药市场规模达到 509 亿美元,预计到 2030 年将实现利润丰厚的增长,达到 1013 亿美元。在预测期内(2023-2030 年),全球控释给药市场预计将呈现 9.2% 的复合年增长率。
控释系统可实现药物的长期持续、有序释放。这种调节释放有助于将治疗药物浓度保持在适当范围内,最大限度地提高疗效。它可以减少给药次数,保证持续供药,从而提高患者的依从性,达到更好的治疗效果。
此外,由于制药公司积极应对不断变化的市场需求,并持续投资开发控释给药方法,因此极大地促进了需求。
全球老年人口和儿童人口的不断增长是推动市场扩大的主要原因之一,这主要是由于这些年龄段的人普遍不遵从处方治疗。老年人的身体、精神和生物功能受损,影响了他们的用药。
例如,世卫组织指出,所有国家在确保其卫生和社会系统做好准备利用这一人口结构转变方面都面临重大挑战。到 2050 年,80% 的老年人将生活在中低收入国家。人口老龄化的速度大大高于过去。
2020 年,60 岁及以上人口的数量将超过 5 岁以下的年轻人。从 2015 年到 2050 年,全球 60 岁以上人口的比例将增加近一倍,从 12%增至 22%。因此,不断增长的老年人口将有助于推动市场扩张。
据预测,主要企业为应对控释给药不断增长的需求而开展的活动和实施的战略也将推动市场扩张。例如,2020 年 10 月,德国赢创工业集团(Evonik Industries AG)推出了一种口服给药技术 Eudratec Fasteric,该技术可提高口服药物的肠道吸收率,其靶点位于吸收窗口较窄的小肠上段。
此外,该技术可使用传统器械快速高效地加工,并与多种口服剂型兼容,包括多颗粒、片剂和胶囊。市场将因上述因素而扩大。
开发按需控释给药系统在技术上具有挑战性。它需要整合复杂的机制,以触发药物释放来响应特定的刺激或外部信号。设计这种能精确控制药物释放速率和剂量的系统非常复杂,通常需要先进的材料和工程技术。
由于需要专门的材料、技术和制造工艺,开发按需控释系统的成本可能很高。此外,这些系统的复杂性可能会增加生产成本,使其更难以负担和广泛使用。因此,上述因素将限制市场的增长。
COVID-19 大流行对控释给药领域产生了积极和消极的影响。由于对 COVID-19 疫苗的迫切需求,控释疫苗给药系统的开发受到了极大重视。这些系统旨在提高疫苗疗效、减少所需剂量并改善患者的依从性。
人们一直在努力开发长效疫苗制剂,以提供持续的免疫反应,并消除对频繁加强剂的需求。大流行导致医疗保健和制药研究方面的资金和投资增加。这为控释给药系统的开发创造了新的机会。
据估计,俄乌冲突对全球控释给药市场的影响不大,原因是该地区的主要市场参与者较少。不过,在预测期内,原材料进出口的影响预计对全球控释给药市场的增长影响不大。
The global controlled release drug delivery market reached US$ 50.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 101.3 billion by 2030. The global controlled release drug delivery market is expected to exhibit a CAGR of 9.2% during the forecast period (2023-2030).
Controlled release systems enable the sustained and regulated release of medications over a long period of time. This regulated distribution helps to keep therapeutic medication concentrations within the appropriate range, maximising therapy efficacy. It can increase patient compliance by reducing drug administration frequency and guaranteeing continuous drug supply, resulting in better therapeutic outcomes.
Additionally, pharmaceutical companies, who operate in a fiercely competitive and fragmented industry, have greatly boosted demand as a result of their proactive response to evolving market demands and continued investments in developing controlled-release drug delivery methods.
The growing geriatric and paediatric population worldwide is one of the primary reasons driving market expansion, owing largely to non-adherence to prescription regimens, which is quite common among these age groups. Geriatric people have impaired physical, mental, and biological functioning, which affect their medication usage.
For instance, according to WHO, all countries have significant challenges in ensuring that their health and social systems are prepared to capitalise on this demographic transformation. By 2050, 80% of the elderly will live in low- and middle-income countries. The population is ageing at a considerably higher rate than in the past.
In 2020, the number of persons aged 60 and more will outnumber youngsters under the age of five. Between 2015 and 2050, the fraction of the global population over the age of 60 will nearly double, from 12% to 22%. As a result, the growing senior population will aid to boost market expansion.
The increased activities and strategies implemented by key players to deal with the growing demand for controlled release medicine delivery are also predicted to fuel market expansion. For instance, in October 2020, Evonik Industries AG, a German pharmaceutical company, has introduced Eudratec Fasteric, an oral drug delivery technology that improves intestinal absorption for oral drug products that target sites in the upper small intestine with a narrow absorption window.
Furthermore, it can be processed rapidly and efficiently using conventional instruments and is compatible with a wide range of oral dose forms, including multiarticulate, tablets, and capsules. The market will expand as a result of the aforementioned factors.
Developing on-demand controlled release drug delivery systems is technically challenging. It requires the integration of sophisticated mechanisms to trigger drug release in response to specific stimuli or external signals. Designing such systems with precise control over drug release rates and dosages is complex and often requires advanced materials and engineering techniques.
Developing on-demand controlled release systems can be costly due to the need for specialized materials, technologies, and manufacturing processes. Additionally, the complexity of these systems may increase the production costs, making them less affordable and accessible for widespread use. Thus, above factors will restrict the market growth.
The COVID-19 pandemic has had both positive and negative impacts on the field of controlled release drug delivery. With the urgent need for COVID-19 vaccines, there has been a significant emphasis on developing controlled release vaccine delivery systems. These systems aim to enhance vaccine efficacy, reduce the number of doses required, and improve patient compliance.
Efforts have been made to develop long-acting vaccine formulations that provide sustained immune response and eliminate the need for frequent boosters. The pandemic has led to increased funding and investment in healthcare and pharmaceutical research. This has created new opportunities for the development of controlled release drug delivery systems.
The Russia-Ukraine conflict is estimated to have a moderate impact on the global controlled release drug delivery market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global controlled release drug delivery market growth over the forecast period.
The global controlled release drug delivery market is segmented based on release mechanism, technology, route of administration and region.
During the projection period, targeted drug delivery is expected to dominate the market. This is mainly due to expanding demand, as well as a growing geriatric and paediatric population. For instance, In 2021, there were about 26.2 million children between the ages of 12 and 17 years old living in the United States. On the other hand, there were about 22.9 million children between the ages of zero and five years old in the country.
Additionally, when compared to typical delivery methods, targeted delivery systems achieve a longer therapeutic effect by delivering medications at the target site at predetermined drug release kinetics. Furthermore, the increasing number of product launches as a result of the increased benefits afforded by targeted delivery are likely to support the segment's growth.
Due to increased R&D efforts and the presence of large pharmaceutical companies in the region. With an increase in patients suffering from chronic diseases such as cancer, diabetes, and COPD, the regional market is expected to grow steadily in the next years.
For instance, according to EUROSTAT, In 2020, cancer was the second highest cause of death in the EU, accounting for 1.2 million deaths, or 23.0% of all deaths in the EU. Cancer claimed a greater share of male mortality (24.9%) than female deaths (20.0%). As a result, the previously mentioned factors will dominate market growth.
The major global players in the controlled release drug delivery market include: Johnson and Johnson, Coating Place, Inc, Corium International, Inc, Depomed, Inc, Pfizer, Inc, Biogen, GlaxoSmithKline, Novartis, Orbis Biosciences, Inc., Merck and Co among others.
The global controlled release drug delivery market report would provide approximately 53 tables, 54 figures and 195 Pages.
Australia
LIST NOT EXHAUSTIVE